In one specific case, an EGFR-mutant NSCLC patient (possessing an EGFR exon 19 deletion) was initially treated with multiple rounds of early-generation EGFR inhibitors but developed resistance via acquisition of the EGFR T790M gatekeeper mutation [44]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.